Contact Us
Contact Us

All Results

Latest Company News DYNAMIKA Spotlight Events IAG Partnerships Industry Digest Knowledge Base
Bar chart showing how GLP‑1 drugs are moving beyond obesity treatment into multiple clinical indications with growing evidence.
April 8, 2026
Obesity Is a Catalyst for Change: Imaging the New Era of GLP‑1 Trials
Arthritis clinical trials using quantitative DCE-MRI imaging to measure synovitis and inflammation in the knee joint.
March 31, 2026
Quantitative Imaging in Arthritis Clinical Trials: Redefining How Inflammation Is Measured
MRI hand imaging and DYNAMIKA™ branding illustrating DAVIX MRI biomarker in systemic sclerosis clinical trials.
March 30, 2026
How MRI-Driven DAVIX Became Part of DYNAMIKA™: From Research Collaboration to Clinical Trial Innovation
MRI of thigh muscles showing inflammatory changes used in IAG clinical trial imaging for CAR‑T autoimmune therapies.
March 30, 2026
Clinical Trial Imaging in CAR-T Autoimmune Therapies: A Strategic Lever for Recruitment, Response, and Regulatory Confidence
CT chest scan showing malignant pleural mesothelioma rind-like pleural thickening used to assess treatment response in mesothelioma drug development imaging studies.
March 29, 2026
Mesothelioma Drug Development & Imaging: The Complete Guide to mRECIST, iRECIST & Imaging CRO Support
Brain MRI scan for autoimmune disease research.
March 23, 2026
Advancing Autoimmune Disease Research: The Role of MRI in Idiopathic Inflammatory Myopathies
Image Analysis Group (IAG) at HBI 2026 pharma services panel in Paris discussing AI-driven imaging for clinical trials.
Company News March 17, 2026
Image Analysis Group (IAG) to Join High-Profile Pharma Services Panel at HBI 2026 in Paris
AICPA SOC 2 logo indicating independently audited controls for Image Analysis Group (IAG)
March 16, 2026
IMAGE ANALYSIS GROUP (IAG) ACHIEVES SOC 2 TYPE II CERTIFICATION
Example 18F-NaF PET/MRI from the S-OLARIS trial showing a 43% reduction in sacroiliac joint SUVmax at week 12, illustrating SLK’s deep, disease‑modifying effects on bone remodelling in axial spondyloarthritis.
March 13, 2026
Beyond the MRI: How PET Imaging is Redefining Drug Development in Axial Spondyloarthritis
;